Entity family

Browse drugs

Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.

3articles mentioning drugs

3drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: CTLA-4 ×

CTLA-4

This drug is selected. Its supporting articles are shown below.

Articles mentioning CTLA-4

3 articles · page 1 of 1

Incidence of fractures in patients with solid cancers treated with immune checkpoint inhibitors: a systematic review and meta-analysis of randomised controlled trials

bmjonc · full text · 2025-11-24 · 1 matching annotations

86.7%

nivolumab ipilimumab pembrolizumab tremelimumab atezolizumab avelumab durvalumab cemiplimab ICI zoledronate+1 more

…ith filters for RCTs. We restricted our analysis to ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab …

461 Circadian control of the tumor immune microenvironment determines immune checkpoint inhibitor efficacy

jitc · abstract · 2025-11-04 · 1 matching annotations

81.5%

ipilimumab Nivolumab sunitinib nab-paclitaxel Atezolizumab CTLA-4 UT Southwestern Medical Center N Engl J Med

…23–34.Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cel…

632 In situ APMV-4 vaccination achieves systemic tumor clearance and long-term antitumor immunity, priming response to sub-therapeutic dosing of aCTLA-4 in colorectal carcinoma

jitc · abstract · 2025-11-04 · 1 matching annotations

82.5%

APMV-4 Ipilimumab aCTLA-4 CTLA-4 Icahn School of Medicine at Mount Sinai CRC

… tumors and tumor draining lymph nodes to unveil the effects of APMV-4 ISV on host immune responses. Ex vivo splenocyte stimulation wa…